Bank of America
SRPT icon

Bank of America’s Sarepta Therapeutics SRPT Stock Holding History

Bank of America’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-50,900
Closed -$4.91M – 8159
2023
Q4 		$4.91M Sell
50,900
-40,100
-44% -$3.85M ﹤0.01% 3571
2023
Q3 		$11M Buy
91,000
+80,100
+735% +$9.05M ﹤0.01% 2626
2023
Q2 		$1.25M Sell
10,900
-71,300
-87% -$9.19M ﹤0.01% 4604
2023
Q1 		$11.3M Buy
82,200
+54,500
+197% +$7.07M ﹤0.01% 2698
2022
Q4 		$3.59M Buy
27,700
+20,700
+296% +$2.4M ﹤0.01% 3722
2022
Q3 		$774K Sell
7,000
-19,100
-73% -$1.93M ﹤0.01% 5073
2022
Q2 		$1.96M Buy
26,100
+19,100
+273% +$1.41M ﹤0.01% 4331
2022
Q1 		$547K Hold
7,000
– – ﹤0.01% 5765
2021
Q4 		$630K Buy
+7,000
New +$598K ﹤0.01% 5670
2021
Q1 		– Sell
-51,300
Closed -$8.75M – 7754
2020
Q4 		$8.75M Buy
51,300
+47,400
+1,215% +$7.02M ﹤0.01% 2610
2020
Q3 		$548K Buy
+3,900
New +$593K ﹤0.01% 4647
2019
Q3 		– Sell
-200,500
Closed -$30.5M – 7485
2019
Q2 		$30.5M Buy
+200,500
New +$24.4M ﹤0.01% 1494
2019
Q1 		– Sell
-25,000
Closed -$2.73M – 7395
2018
Q4 		$2.73M Hold
25,000
– – ﹤0.01% 3579
2018
Q3 		$4.04M Hold
25,000
– – ﹤0.01% 3388
2018
Q2 		$3.31M Sell
25,000
-9,000
-26% -$849K ﹤0.01% 3550
2018
Q1 		$2.52M Buy
+34,000
New +$2.27M ﹤0.01% 3704
2017
Q4 		– Sell
-40,000
Closed -$1.81M – 7238
2017
Q3 		$1.81M Buy
+40,000
New +$1.6M ﹤0.01% 4062
2015
Q1 		– Sell
-402,600
Closed -$5.83M – 7522
2014
Q4 		$5.83M Sell
402,600
-700
-0.2% -$11.9K ﹤0.01% 2417
2014
Q3 		$8.51M Buy
403,300
+400
+0.1% +$9.03K ﹤0.01% 2077
2014
Q2 		$12M Buy
402,900
+94,900
+31% +$3M ﹤0.01% 1775
2014
Q1 		$7.4M Buy
308,000
+23,000
+8% +$586K ﹤0.01% 2032
2013
Q4 		$5.8M Buy
285,000
+4,900
+2% +$146K ﹤0.01% 2339
2013
Q3 		$13.2M Buy
280,100
+276,300
+7,271% +$10.6M 0.01% 1554
2013
Q2 		$145K Buy
+3,800
New +$136K ﹤0.01% 5905

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America's SRPT Position: Q1 2026 in Review

Bank of America increased its Sarepta Therapeutics (SRPT) stake by 27% in Q1 2026, buying an estimated $8.74M and bringing the position to 2,145,926 shares worth $46.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.

Bank of America first reported a position in SRPT in Q2 2013 and has held it in 52 quarters since. The position peaked at $117M in Q4 2023. 341 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • Bank of America held 2,145,926 shares of Sarepta Therapeutics worth $46.7M as of Q1 2026.
  • Bank of America bought 451,336 Sarepta Therapeutics shares in Q1 2026, an estimated $8.74M.
  • Sarepta Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1647 holding.
  • Bank of America first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Sarepta Therapeutics position peaked at $117M in Q4 2023.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.